[go: up one dir, main page]

JPH08169836A - Agent for sodium bicarbonate dialysis and its production - Google Patents

Agent for sodium bicarbonate dialysis and its production

Info

Publication number
JPH08169836A
JPH08169836A JP6169945A JP16994594A JPH08169836A JP H08169836 A JPH08169836 A JP H08169836A JP 6169945 A JP6169945 A JP 6169945A JP 16994594 A JP16994594 A JP 16994594A JP H08169836 A JPH08169836 A JP H08169836A
Authority
JP
Japan
Prior art keywords
layer
organic acid
bicarbonate
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6169945A
Other languages
Japanese (ja)
Other versions
JP3647898B2 (en
Inventor
Taiji Nakano
泰治 中野
Toshimi Miyoshi
稔美 三好
Shigeyuki Nomura
繁幸 野村
Shigeyuki Yumikari
繁幸 弓狩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MORISHITA ROUSSEL KK
Morishita Pharmaceuticals Co Ltd
Original Assignee
MORISHITA ROUSSEL KK
Morishita Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MORISHITA ROUSSEL KK, Morishita Pharmaceuticals Co Ltd filed Critical MORISHITA ROUSSEL KK
Priority to JP16994594A priority Critical patent/JP3647898B2/en
Publication of JPH08169836A publication Critical patent/JPH08169836A/en
Application granted granted Critical
Publication of JP3647898B2 publication Critical patent/JP3647898B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

PURPOSE: To obtain an agent for sodium bicarbonate dialysis, containing an electrolyte, an organic acid and glucose, having a laminar structure containing each component in each layer successively laminated from the 1st layer on a core, keeping excellent stability over a long period, effective for preventing the deposition of precipitate and having easy handleability. CONSTITUTION: This dialyzing agent consists of a core composed of sodium chloride, a 1st layer containing a calcium salt and/or a magnesium salt and free from organic acid and bicarbonate, a 2nd layer containing an organic acid and free from calcium salt, magnesium salt and bicarbonate and a 3rd layer containing a bicarbonate and free from calcium salt, magnesium salt and organic acid. These layers are successively laminated on the core. The lamination is carried out by using a glucose solution as a binder and the agent is formed preferably in a spherical laminated form and filled together with a desiccant in a moistureproof air-tight container in carbon dioxide gas stream. The reaction between the constituent components can be prevented because the organic acid and the bicarbonate are laminated in the dialyzing agent in separated state.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、炭酸水素イオンを含有
する透析液、すなわち重曹透析液を調製するための積層
製剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a layered preparation for preparing a dialysate containing hydrogen carbonate ions, that is, a sodium bicarbonate dialysate.

【0002】[0002]

【従来の技術】従来、血液透析を行う場合、以下に示す
ような組成の重曹透析液が用いられている。 Na+ 120〜150 mEq/l K+ 0.5〜3.0 mEq/l Ca++ 1.5〜4.5 mEq/l Mg++ 0〜2.0 mEq/l Cl- 90〜135 mEq/l HCO3 - 20〜 35 mEq/l CH3CO2 - 5〜 10 mEq/l ブドウ糖 0〜2.5 g/l しかし、このような組成の透析液は、一人一回の透析に
約350リットルもの大量が使用され、しかも製剤的に
不安定なことから、使用直前に調製せざるを得ず、煩雑
な作業を要するものであった。
2. Description of the Related Art Conventionally, when performing hemodialysis, a sodium bicarbonate dialysate having the following composition has been used. Na + 120~150 mEq / l K + 0.5~3.0 mEq / l Ca ++ 1.5~4.5 mEq / l Mg ++ 0~2.0 mEq / l Cl - 90~135 mEq / l HCO 3 - 20~ 35 mEq / l CH 3 CO 2 - 5~ 10 mEq / l glucose 0 to 2.5 g / l, however, dialysate having such a composition is from about 350 to one single dialysis Since a large amount of liter was used and the formulation was unstable, it had to be prepared immediately before use and required complicated work.

【0003】そこで前記作業を軽減するものとして、一
人一回分の包装単位で、必要成分中の炭酸水素ナトリウ
ムを別にした濃厚原液(約11リットル)が市販される
ようになった。しかし、組成中の炭酸水素ナトリウムが
カルシウム塩やマグネシウム塩と反応して炭酸塩の沈澱
を生じるため、現在使用されている透析液は、原液を一
液にすることができず、二液に分けて製品化されてい
る。そのため、運搬、保管場所、取扱い等において十分
改良されたとは言えず、その後も種々の提案がなされて
いる。このような点に鑑み、透析用剤を粉末化しようと
する試みがなされている。例えば、特開平3−7433
1号公報には透析液に必要な成分を、カルシウム成分を
含み重曹を含まない群からなる造粒物と、重曹を含みカ
ルシウム成分を含まない群からなる造粒物との混合物に
ついて開示されている。これは、所定量の透析用剤を単
に水に溶解するだけで透析液の調製ができるようにした
ものであるが、pH調整剤として用いられている酢酸
が、カルシウム塩、マグネシウム塩及び重炭酸塩と同時
に溶解するため、不溶性の沈澱が生じたり、炭酸ガスが
発生してpHが高くなり易いという欠点がある。また、
長期保存中にも反応が進行して、凝集が生じたり、含量
の低下を引き起こす等の問題を有している。一方、特開
平2−311418号公報には透析用固体電解質及び液
体酸よりなる粉末状組成物と、炭酸水素ナトリウム及び
ブドウ糖の粉末状組成物と二つの組成物よりなる粉末状
透析用製剤が開示されている。また、特開平4−257
522号公報には透析用電解質成分のうち重曹以外の成
分から選ばれた1種以上からなる群と、重曹を主成分と
する群からなる二剤の造粒物、特開平5−70357号
公報には、透析用電解質、ブドウ糖及び重曹の三成分を
別々の顆粒状組成物とした透析用剤が開示されている。
しかし、これらはいずれも二剤あるいは三剤に分けて製
造されていることから取り扱いについての問題点は何ら
解決されていない。
Therefore, in order to reduce the above-mentioned work, a concentrated stock solution (about 11 liters) in which sodium hydrogen carbonate as a necessary component is excluded has been put on the market in a packaging unit for one person. However, since sodium hydrogen carbonate in the composition reacts with calcium salts and magnesium salts to cause precipitation of carbonate salts, the dialysate currently used cannot be made into one solution as a stock solution, and is divided into two solutions. Have been commercialized. Therefore, it cannot be said that it has been sufficiently improved in transportation, storage place, handling, etc., and various proposals have been made since then. In view of these points, attempts have been made to powder the dialysis agent. For example, JP-A-3-7433
No. 1 discloses a mixture of components necessary for a dialysate, which is a granulated product composed of a group containing a calcium component and no sodium bicarbonate and a granulated product composed of a group containing sodium bicarbonate and not containing a calcium component. There is. This is so that a dialysate can be prepared by simply dissolving a predetermined amount of dialysis agent in water. However, acetic acid used as a pH adjusting agent contains calcium salt, magnesium salt and bicarbonate. Since it dissolves at the same time as the salt, it has the drawbacks that insoluble precipitates occur and carbon dioxide gas is generated, which tends to raise the pH. Also,
There are problems that the reaction proceeds even during long-term storage, aggregation occurs, and the content decreases. On the other hand, Japanese Unexamined Patent Publication No. 2-311418 discloses a powdery dialysis preparation comprising a powdery composition comprising a dialysis solid electrolyte and a liquid acid, a sodium hydrogencarbonate and glucose powdery composition, and two compositions. Has been done. In addition, Japanese Patent Laid-Open No. 4-257
No. 522, a granule of two agents consisting of a group consisting of one or more components selected from components other than baking soda among electrolyte components for dialysis and a group containing sodium bicarbonate as a main component, JP-A-5-70357. Discloses a dialysis agent in which three components of a dialysis electrolyte, glucose and sodium bicarbonate are prepared as separate granular compositions.
However, since all of them are manufactured by dividing them into two or three parts, no problems in handling have been solved.

【0004】[0004]

【発明が解決しようとする課題】本発明の課題は、長期
保存に対して安定性に優れ、しかも使用時に各成分が順
次溶解することにより沈澱の析出を防止でき、かつ容易
に調製できる重曹透析用剤を提供することにある。
DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention The subject of the present invention is baking soda dialysis, which is excellent in stability for long-term storage, can prevent precipitation due to sequential dissolution of each component during use, and can be easily prepared. It is to provide an agent.

【0005】[0005]

【課題を解決するための手段】本発明者らは、透析用剤
に必要な各電解質及びブドウ糖の安定性及び吸湿性につ
いて考慮しながら、pH調整剤も含めた安定な積層製剤
を提供することについて鋭意研究した。その結果、核に
塩化ナトリウムを用いて、カルシウム塩又は/及びマグ
ネシウム塩を含み有機酸及び重炭酸塩を含まない群、有
機酸を含みカルシウム塩、マグネシウム塩及び重炭酸塩
を含まない群及び重炭酸塩を含みカルシウム塩、マグネ
シウム塩及び有機酸を含まない群を積層するとき、カル
シウム塩、マグネシウム塩、有機酸及び重炭酸塩以外の
成分から選ばれた群を介して順次積層することにより前
記課題が解決できることを見い出し、本発明を完成し
た。
[Means for Solving the Problems] The present inventors provide a stable multi-layered preparation including a pH adjusting agent while considering the stability and hygroscopicity of each electrolyte and glucose required for a dialysis agent. I researched earnestly. As a result, sodium chloride was used for the nucleus, a group containing calcium salt and / or magnesium salt and containing no organic acid and bicarbonate, a group containing organic acid and containing no calcium salt, magnesium salt and bicarbonate, and heavy salt. When laminating a group containing a carbonate but not a calcium salt, a magnesium salt and an organic acid, by sequentially laminating the group selected from components other than the calcium salt, the magnesium salt, the organic acid and the bicarbonate, The inventors have found that the problems can be solved and completed the present invention.

【0006】すなわち、本発明は、電解質、有機酸及び
ブドウ糖を含有する透析用剤であって、前記有機酸が酢
酸、乳酸、クエン酸、酒石酸、マレイン酸、オキサロ酢
酸、イソクエン酸及びリンゴ酸からなる群から選ばれた
一種又は二種以上であり、積層製剤が、核、第一層、第
二層及び第三層の多層構造を有し、核が塩化ナトリウム
である透析用剤において、第一層はカルシウム塩又は/
及びマグネシウム塩を含み有機酸及び重炭酸塩を含まな
い層であり、第二層は二層以上に分けて積層され、かつ
有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸
塩を含まない層であり、第三層は重炭酸塩を含みカルシ
ウム塩、マグネシウム塩及び有機酸を含まない層である
ことを特徴とする重曹透析用剤である。この積層製剤
は、炭酸ガス気流中防湿を施した気密容器内に充填し、
乾燥剤と共に収納される。
That is, the present invention is a dialysis agent containing an electrolyte, an organic acid and glucose, wherein the organic acid is selected from acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid. 1 or 2 or more selected from the group consisting of, the laminated preparation has a multilayer structure of a core, a first layer, a second layer and a third layer, the core is sodium chloride, in the dialysis agent, One layer is calcium salt or /
And a layer containing a magnesium salt and containing no organic acid and bicarbonate, the second layer being a laminate of two or more layers and containing an organic acid and containing no calcium salt, magnesium salt or bicarbonate salt. The third layer is a sodium bicarbonate dialysis agent characterized by being a layer containing bicarbonate and not containing calcium salt, magnesium salt and organic acid. This laminated preparation is filled in a moisture-proof airtight container in a carbon dioxide gas stream,
Stored with desiccant.

【0007】本発明の重曹透析用剤に含まれる成分の好
ましい配合範囲を、透析液調製後の組成範囲で示せば下
記の如くであり、そのpHは7.0〜8.0、より好ま
しくは7.2〜7.6である。 Na+ 120〜150 mEq/l K+ 0〜 4 mEq/l Ca++ 1〜 6 mEq/l Mg++ 0〜 2 mEq/l Cl- 90〜135 mEq/l CH3CO2 - 2〜 15 mEq/l HCO3- 10〜 40 mEq/l ブドウ糖 0〜 10 g/l
The preferred blending range of the components contained in the sodium bicarbonate dialysis agent of the present invention is shown below in terms of the composition range after preparation of the dialysate, and the pH thereof is 7.0 to 8.0, more preferably. It is 7.2 to 7.6. Na + 120~150 mEq / l K + 0~ 4 mEq / l Ca ++ 1~ 6 mEq / l Mg ++ 0~ 2 mEq / l Cl - 90~135 mEq / l CH 3 CO 2 - 2~ 15 mEq / l HCO 3 - 10~ 40 mEq / l glucose 0 to 10 g / l

【0008】本発明の重曹透析用剤の製造に当たり、化
合物を選択し配合割合を設定する場合は、例えば上記に
基づいて各成分の濃度を設定し、各成分を供給できる化
合物の組合せにより逆算すればよい。
In the production of the sodium bicarbonate dialysis agent of the present invention, when the compounds are selected and the mixing ratio is set, for example, the concentration of each component is set based on the above, and the back calculation is performed by the combination of the compounds capable of supplying each component. Good.

【0009】本発明に使用される電解質は、薬理学的に
許容されるものでなければならない。例えば、炭酸水素
ナトリウム、炭酸水素カリウム、塩化ナトリウム、塩化
カリウム、塩化カルシウム、塩化マグネシウム、酢酸ナ
トリウム、酢酸カリウム、グルコン酸カルシウム等をあ
げることができる。本発明を構成する積層製剤は、上記
のような電解質と共に、血中に含まれるその他の成分、
例えばブドウ糖を含むことができる。
The electrolyte used in the present invention must be pharmacologically acceptable. For example, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, potassium acetate, calcium gluconate and the like can be mentioned. The laminated preparation constituting the present invention, together with the electrolyte as described above, other components contained in blood,
For example, glucose can be included.

【0010】前記積層製剤は、カルシウム塩及び/又は
マグネシウム塩を含み有機酸及び重炭酸塩を含まない群
(第一層)、有機酸を含みカルシウム塩、マグネシウム
塩及び重炭酸塩を含まない群(第二層)及び重炭酸塩を
含みカルシウム塩、マグネシウム塩及び有機酸を含まな
い群(第三層)が重要である。すなわち、カルシウム塩
及び/又はマグネシウム塩を含み有機酸及び重炭酸塩を
含まない群と重炭酸塩を含みカルシウム塩、マグネシウ
ム塩及び有機酸を含まない群をカルシウム塩、マグネシ
ウム塩、有機酸及び重炭酸塩以外の成分から選ばれた群
を介して接触しないように積層することにより、カルシ
ウム塩及びマグネシウム塩が重炭酸塩と反応することを
防止することができる。また有機酸を含みカルシウム
塩、マグネシウム塩及び重炭酸塩を含まない群と重炭酸
塩を含みカルシウム塩、マグネシウム塩及び有機酸を含
まない群をカルシウム塩、マグネシウム塩、有機酸及び
重炭酸塩以外の成分から選ばれた群を介して接触しない
ように積層することにより重炭酸塩と有機酸の反応を防
ぐことができる。すなわち、透析液の調製の際に、積層
製剤の外層から蒸留水に順次溶解して、pHが中性から
微アルカリに調整されるため、炭酸ガスの発生を、また
カルシウム塩やマグネシウム塩が最後に溶解するため、
炭酸カルシウム及び炭酸マグネシウムの沈澱生成を防ぐ
ことができる。また所望により積層順序を変えてもよい
し、前記第一層、第二層及び第三層は、さらに二層以上
の多層より構成されていてもよい。
The layered preparation comprises a group containing calcium salt and / or magnesium salt and no organic acid and bicarbonate (first layer), a group containing organic acid and no calcium salt, magnesium salt and bicarbonate salt. The (second layer) and the group containing bicarbonate and calcium salt, magnesium salt and organic acid (third layer) are important. That is, a group containing a calcium salt and / or a magnesium salt and not containing an organic acid and a bicarbonate salt, and a group containing a bicarbonate salt and containing no calcium salt, a magnesium salt and an organic acid are treated with a calcium salt, a magnesium salt, an organic acid and a bicarbonate salt. By stacking so as not to contact via a group selected from components other than carbonate, it is possible to prevent the calcium salt and the magnesium salt from reacting with the bicarbonate salt. In addition, except for calcium salts, magnesium salts, organic acids and bicarbonates, the groups containing organic acids and not containing calcium salts, magnesium salts and bicarbonates and those containing bicarbonates and containing calcium salts, magnesium salts and organic acids are excluded. It is possible to prevent the reaction between the bicarbonate and the organic acid by laminating the components so that they do not come in contact with each other via the group selected from the above components. That is, when the dialysate is prepared, it is sequentially dissolved from the outer layer of the laminated preparation in distilled water, and the pH is adjusted from neutral to slightly alkaline, so that the generation of carbon dioxide gas and the last of calcium salt and magnesium salt are generated. Because it dissolves in
It is possible to prevent precipitation of calcium carbonate and magnesium carbonate. If desired, the stacking order may be changed, and the first layer, the second layer, and the third layer may be further composed of two or more layers.

【0011】以下に本発明の積層操作を述べる。本発明
の製造方法は、核に順次積層する工程からなり、一般的
に使用される造粒及びコーティング装置によって実施さ
れる。例えば、使用する群をカルシウム塩及び/又はマ
グネシウム塩を含み有機酸及び重炭酸塩を含まない群、
有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸
塩を含まない群、重炭酸塩含みカルシウム塩、マグネシ
ウム塩及び有機酸を含まない群及びカルシウム塩、マグ
ネシウム塩、有機酸及び重炭酸塩以外の成分から選ばれ
た群に分け、各群の成分を適宜サンプルミル(不二パウ
ダル社製)等の粉砕機で微粉化する。次に核の塩化ナト
リウム結晶粒子を遠心流動型コーティング造粒装置に入
れ、回転させ、結合剤として適量のブドウ糖溶液を噴霧
しながら前記微粉末を順次粉末添加することによって球
形の積層製剤が得られる。
The laminating operation of the present invention will be described below. The manufacturing method of the present invention comprises steps of sequentially stacking on the core, and is carried out by a commonly used granulating and coating apparatus. For example, the group to be used is a group containing calcium salt and / or magnesium salt and not containing organic acid and bicarbonate,
Organic acid-containing calcium salt, magnesium salt and bicarbonate-free group, bicarbonate salt-containing calcium salt, magnesium salt and organic acid-free group and components other than calcium salt, magnesium salt, organic acid and bicarbonate salt The ingredients of each group are appropriately pulverized with a pulverizer such as a sample mill (manufactured by Fuji Paudal Co.). Next, the sodium chloride crystal particles of the nucleus are placed in a centrifugal fluidized coating granulator, rotated, and the fine powder is sequentially added while spraying an appropriate amount of glucose solution as a binder to obtain a spherical laminated preparation. .

【0012】本発明の重曹透析用剤の剤型としては、核
の表面に、第一層から順次積層される球形の積層製剤が
好ましい。
The dosage form of the sodium bicarbonate dialysis agent of the present invention is preferably a spherical multi-layered preparation which is sequentially laminated on the surface of the core from the first layer.

【0013】前記有機酸としては、例えば酢酸、乳酸、
クエン酸、酒石酸、マレイン酸、オキサロ酢酸、イソク
エン酸、リンゴ酸等をあげることができ、とりわけクエ
ン酸が好ましい。酸の使用量は、透析液のpHが7.0
〜8.0の範囲になるように加えるのが好ましい。より
好ましい範囲はpH7.2〜7.6である。これらの有
機酸は1種のみならず2種以上を混合して用いることも
できる。
Examples of the organic acid include acetic acid, lactic acid,
Examples thereof include citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid, with citric acid being particularly preferred. The amount of acid used is such that the pH of the dialysate is 7.0.
It is preferable to add it so as to be in the range of to 8.0. A more preferable range is pH 7.2 to 7.6. These organic acids may be used alone or in combination of two or more.

【0014】本発明の積層製剤の製造方法に用いられる
結合剤は、成分中のブドウ糖が使用されているため安全
であり、また結合力が強いので高強度で粉状化しにくい
積層製剤を得ることができる。ブドウ糖は溶媒に適宜溶
解して用いられるが、好ましい濃度としては0.5〜5
5W/W%が適当である。溶媒としては、製剤化に用いら
れ、ブドウ糖が溶解するものであれば特に限定されない
が、好ましくは水あるいは水とエタノールの混合溶媒で
ある。
The binder used in the method for producing a laminated preparation of the present invention is safe because glucose is used as a component, and since the binding strength is strong, a laminated preparation having high strength and hardly powdered can be obtained. You can Glucose is used by appropriately dissolving it in a solvent, and a preferable concentration is 0.5 to 5
5 W / W% is suitable. The solvent is not particularly limited as long as it is used for formulation and dissolves glucose, but water or a mixed solvent of water and ethanol is preferable.

【0015】本発明の重曹透析用剤の保存容器に用いら
れる素材としては、実質的に防湿性及びガス非透過性の
ものであれば特に限定されないが、例えば、ポリエチレ
ン、ポリプロピレン、ポリ塩化ビニル等あるいはアルミ
ニウムの如き金属箔、ナイロン、セロファン等を、適宜
二層ないし多層に積層したラミネートフィルムがあげら
れる。
The material used for the storage container for the sodium bicarbonate dialysis agent of the present invention is not particularly limited as long as it is substantially moisture-proof and gas-impermeable, and examples thereof include polyethylene, polypropylene and polyvinyl chloride. Alternatively, a laminate film in which a metal foil such as aluminum, nylon, cellophane, etc. are appropriately laminated in two layers or multiple layers can be given.

【0016】前記のような包装形態の気密性容器に、炭
酸ガス気流中乾燥剤と共に密封すると、より安定性を向
上させることができるので好都合である。乾燥剤として
はシリカゲル、塩化カルシウム、炭酸カルシウム等が用
いられる。
It is convenient to seal the airtight container in the above-mentioned packaging form together with a desiccant in a carbon dioxide gas stream because the stability can be further improved. As the desiccant, silica gel, calcium chloride, calcium carbonate or the like is used.

【0017】[0017]

【作用】このようにして得られる重曹透析用剤は、有機
酸と重炭酸塩を接触しないように積層しているので成分
間の反応を防ぐことができる。また、透析液を調製する
際は、特にpH調整を行わなくても重炭酸塩から順次溶
解して、液のpHが中性から微アルカリ性に調整され、
最後にカルシウム塩及びマグネシウム塩が溶解するの
で、炭酸塩の沈澱が生成しない。
The sodium dialysis agent thus obtained is laminated so that the organic acid and the bicarbonate are not in contact with each other, so that the reaction between the components can be prevented. Further, when preparing a dialysis solution, the pH of the solution is adjusted from neutral to slightly alkaline by sequentially dissolving from bicarbonate without any particular pH adjustment.
Finally, the calcium and magnesium salts dissolve, so that no carbonate precipitate forms.

【0018】[0018]

【実施例】以下、実施例及び試験例に基づいて、本発明
をさらに詳細に説明するが、本発明はこれらの実施例に
限定されるものではない。 〔実施例1〕塩化マグネシウム17.9g、塩化カルシウム
38.7g及び塩化カリウム26.1gを万能攪拌機(品川工業
製、SD-02型)で攪拌し、サンプルミル(不二パウダル
製、粉砕機KIIW-1)で粉砕して第一層の微粉末を
得た。同様にして、クエン酸35g、塩化ナトリウム105
gを混合、粉砕して第二層(内層)の微粉末を得た。ブ
ドウ糖91.0g、酢酸ナトリウム85.9g及び塩化ナトリウ
ム100.9gを前記同様の操作を行い第二層(中間層)の
微粉末を得た。第二層(外層)として塩化ナトリウム15
7.5gを粉砕し微粉末を得た。さらに第三層として炭酸
水素ナトリウム441gを粉砕し微粉末を得た。次に粒子
径350〜500μmの塩化ナトリウム700gを遠心流動造粒
コーチング装置(フロイント産業社製、CF-360S型)に
入れ、回転させ(回転数200rpm)、ブドウ糖溶液を
噴霧しながら第一層、第二層(内層)、第二層(中間
層)、第二層(外層)及び第三層の順に微粉末を添加
し、球形の積層製剤を得た。得られた積層製剤を常法に
より乾燥し目的の透析用剤を得た。
The present invention will be described in more detail based on the following examples and test examples, but the present invention is not limited to these examples. [Example 1] 17.9 g of magnesium chloride and calcium chloride
Stir 38.7 g and potassium chloride 26.1 g with a universal stirrer (SD-02 type, manufactured by Shinagawa Kogyo) and pulverize with a sample mill (Fuji Paudal, pulverizer KIIW-1) to obtain a fine powder for the first layer. It was Similarly, citric acid 35g, sodium chloride 105
g was mixed and pulverized to obtain a fine powder of the second layer (inner layer). Glucose (91.0 g), sodium acetate (85.9 g) and sodium chloride (100.9 g) were treated in the same manner as above to obtain a fine powder for the second layer (intermediate layer). Sodium chloride 15 as the second layer (outer layer)
7.5 g was crushed to obtain a fine powder. Further, 441 g of sodium hydrogen carbonate was crushed as a third layer to obtain a fine powder. Next, 700 g of sodium chloride having a particle diameter of 350 to 500 μm is put into a centrifugal fluidized granulation coating device (CF-360S type manufactured by Freund Sangyo Co., Ltd.) and rotated (rotation speed 200 rpm), while spraying the glucose solution, the first layer, A fine powder was added in the order of the second layer (inner layer), the second layer (intermediate layer), the second layer (outer layer) and the third layer to obtain a spherical laminated preparation. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.

【0019】〔実施例2〕塩化マグネシウム17.9g、塩
化カルシウム38.7g及び塩化カリウム26.1gを万能攪拌
機で攪拌し、サンプルミルで粉砕して第一層の微粉末を
得た。同様にして、クエン酸35g、塩化ナトリウム105
gを混合、粉砕して第二層(内層)の微粉末を得た。ブ
ドウ糖91.0g及び塩化ナトリウム100.9gを前記同様の
操作を行い第二層(中間層)の微粉末を得た。第二層
(外層)として酢酸ナトリウム85.9g及び塩化ナトリウ
ム157.5gを粉砕し微粉末を得た。さらに第三層として
炭酸水素ナトリウム441gを粉砕し微粉末を得た。次に
粒子径350〜500μmの塩化ナトリウム700gを遠心流動
造粒コーチング装置(フロイント産業社製、CF-360S
型)に入れ、回転させ(回転数200rpm)、ブドウ糖
溶液を噴霧しながら第一層、第二層(内層)、第二層
(中間層)、第二層(外層)及び第三層の順に微粉末を
添加し、球形の積層製剤を得た。得られた積層製剤を常
法により乾燥し、目的の透析用剤を得た。
Example 2 Magnesium chloride (17.9 g), calcium chloride (38.7 g) and potassium chloride (26.1 g) were stirred with a universal stirrer and ground with a sample mill to obtain a fine powder for the first layer. Similarly, citric acid 35g, sodium chloride 105
g was mixed and pulverized to obtain a fine powder of the second layer (inner layer). Glucose 91.0 g and sodium chloride 100.9 g were treated in the same manner as above to obtain a fine powder of the second layer (intermediate layer). As the second layer (outer layer), 85.9 g of sodium acetate and 157.5 g of sodium chloride were pulverized to obtain a fine powder. Further, 441 g of sodium hydrogen carbonate was crushed as a third layer to obtain a fine powder. Next, 700 g of sodium chloride having a particle diameter of 350 to 500 μm is centrifugally fluidized and granulated by a coating device (manufactured by Freund Sangyo Co., Ltd., CF-360S).
Molds) and rotate (rotation speed 200 rpm), spraying the glucose solution, the first layer, the second layer (inner layer), the second layer (intermediate layer), the second layer (outer layer) and the third layer in this order. Fine powder was added to obtain a spherical laminated preparation. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.

【0020】〔実施例3〕転動流動造粒乾燥装置(マル
チプレックス、MP-01型、パウレックス社製)に、粒子
径350〜500μmの塩化ナトリウム700gを入れ、塩化マ
グネシウム17.9g、塩化カルシウム38.7g及び塩化カリ
ウム26.1g精製水193gに溶解した第一層の液をコーテ
ィングした。次に、クエン酸35g、塩化ナトリウム105
gを326.7gの精製水に溶解した第二層(内層)の液をコ
ーティングし、順次、ブドウ糖148.75g、酢酸ナトリウ
ム85.9g及び塩化ナトリウム100.9gを精精水4139.1g
に溶解した第二層(中間層)の液、塩化ナトリウム157.
5gを水472.5gに溶解した第二層(外層)の液をコーテ
ィングした。上記積層された造粒物700gを遠心流動造
粒コーチング装置(フロイント産業社製、CF-360S型)
に入れ、回転させ(回転数200rpm)、ブドウ糖溶液
を噴霧しながらサンプルミルで粉砕した第三層の炭酸水
素ナトリウムの微粉末214g添加し、球形の積層製剤を
得た。得られた積層製剤を常法により乾燥し目的の透析
用剤を得た。
Example 3 700 g of sodium chloride having a particle diameter of 350 to 500 μm was put into a tumbling fluidized granulation drying device (Multiplex, MP-01 type, manufactured by Paulex Co.), and 17.9 g of magnesium chloride and calcium chloride. The first layer liquid dissolved in 38.7 g and 26.1 g of potassium chloride and 193 g of purified water was coated. Next, citric acid 35g, sodium chloride 105
The second layer (inner layer) of 326.7g of purified water is coated, and 148.75g of glucose, 85.9g of sodium acetate and 100.9g of sodium chloride are sequentially purified water 4139.1g.
Liquid of the second layer (intermediate layer) dissolved in, sodium chloride 157.
A second layer (outer layer) solution in which 5 g was dissolved in 472.5 g of water was coated. Centrifugal fluidized granulation coating device (CF-360S type, manufactured by Freund Sangyo) for 700 g of the above-mentioned laminated granules
Then, 214 g of a fine powder of sodium hydrogencarbonate of the third layer crushed by a sample mill was added while spraying the glucose solution, and a spherical laminated preparation was obtained. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.

【0021】〔実施例4〕塩化マグネシウム17.9g、塩
化カルシウム38.7g及び塩化カリウム26.1gを万能攪拌
機(品川工業製、SD-02型)で攪拌し、サンプルミル
(不二パウダル製、粉砕機KIIW-1)で粉砕して第
一層の微粉末を得た。同様にして、クエン酸35g、塩化
ナトリウム105gを混合、粉砕して第二層(内層)の微
粉末を得た。ブドウ糖91.0g、酢酸ナトリウム85.9g及
び塩化ナトリウム258.4gを前記同様の操作を行い第二
層(外層)の微粉末を得た。さらに第三層として炭酸水
素ナトリウム441gを粉砕し微粉末を得た。次に粒子径3
50〜500μmの塩化ナトリウム700gを遠心流動造粒コー
チング装置(フロイント産業社製、CF-360S型)に入
れ、回転させ(回転数200rpm)、ブドウ糖溶液を噴
霧しながら第一層、第二層(内層)、第二層(外層)及
び第三層の順に微粉末を添加し、球形の積層製剤を得
た。得られた積層製剤を常法により乾燥し目的の透析用
剤を得た。
Example 4 Magnesium chloride (17.9 g), calcium chloride (38.7 g) and potassium chloride (26.1 g) were stirred with a universal stirrer (Shinagawa Kogyo, SD-02 type), and a sample mill (Fuji Paudal, crusher KIIW) was used. It was crushed in -1) to obtain a fine powder of the first layer. Similarly, 35 g of citric acid and 105 g of sodium chloride were mixed and pulverized to obtain a fine powder of the second layer (inner layer). Glucose (91.0 g), sodium acetate (85.9 g) and sodium chloride (258.4 g) were treated in the same manner as above to obtain a fine powder for the second layer (outer layer). Further, 441 g of sodium hydrogen carbonate was crushed as a third layer to obtain a fine powder. Then the particle size 3
Put 700 g of 50-500 μm sodium chloride into a centrifugal fluidized granulation coating device (CF-360S type, manufactured by Freund Sangyo Co., Ltd.) and rotate (rotation speed 200 rpm) to spray the glucose solution with the first layer and the second layer ( Fine powder was added in the order of the inner layer), the second layer (outer layer), and the third layer to obtain a spherical laminated preparation. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.

【0022】〔試験例1〕安定性試験 実施例1で得られた透析用剤を、1)乾燥剤及び炭酸ガ
ス置換なし、2)乾燥剤としてシリカゲルを収納、3)
容器を炭酸ガス置換、4)乾燥剤としてシリカゲルを収
納し、かつ容器を炭酸ガス置換の4条件で、それぞれガ
ラス瓶に入れ、密封して40℃に保存した後、色差(△
E)、凝集の有無、溶解後の炭酸水素イオン濃度及びp
Hを測定した。なお、色差は標準白板をを対照とし、色
差計(日本電色工業社製、Σ80型)を用いて測定し
た。炭酸水素イオン及びpHは、試料10.76gを精製水
に溶かして1000mlとし、それぞれイオンクロマトグラフ
ィー(横川電機社製、IC-500S型)及びpHメータ(堀
場製作所製、F-16型)を用いて測定した。それらの結果
を、表1に示した。
[Test Example 1] Stability Test The dialysis agent obtained in Example 1 was used for 1) no desiccant and carbon dioxide substitution, 2) silica gel was stored as a desiccant, 3)
The containers were filled with carbon dioxide gas, 4) Silica gel was stored as a desiccant, and the containers were placed in glass bottles under the four conditions of carbon dioxide gas replacement, sealed and stored at 40 ° C.
E), presence / absence of aggregation, hydrogen carbonate ion concentration after dissolution and p
H was measured. The color difference was measured with a color difference meter (Nippon Denshoku Industries Co., Ltd., Σ80 type) using a standard white plate as a reference. For the hydrogen carbonate ion and pH, 10.76 g of the sample was dissolved in purified water to 1000 ml, and ion chromatography (Yokogawa Denki IC-500S type) and pH meter (Horiba Seisakusho F-16 type) were used, respectively. It was measured. The results are shown in Table 1.

【0023】[0023]

【表1】 [Table 1]

【0024】以上の結果から、シリカゲルと共に収納す
ることにより着色が抑制され、炭酸ガスで置換すること
により炭酸水素イオン含量が安定に維持されることが明
らかとなった。また溶解に際し、いずれも数分以内に、
速やかに溶解した。
From the above results, it has been clarified that the coloration is suppressed by storing it together with silica gel, and the hydrogen carbonate ion content is stably maintained by replacing with carbon dioxide gas. In addition, upon dissolution, within a few minutes,
It quickly dissolved.

【0025】[0025]

【発明の効果】本発明の重曹透析用剤は、前記のように
多層に積層されているので、長期間の安定性に優れてい
る。また、一剤中に必要な成分をすべて含んでいること
から取扱いが容易である。
EFFECT OF THE INVENTION Since the sodium bicarbonate dialysis agent of the present invention is laminated in multiple layers as described above, it is excellent in long-term stability. In addition, it is easy to handle because all the necessary components are contained in one agent.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 // A61M 1/14 511 (A61K 33/00 31:19 31:70) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location // A61M 1/14 511 (A61K 33/00 31:19 31:70)

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 電解質、有機酸及びブドウ糖を含有する
透析用剤であって、前記有機酸が酢酸、乳酸、クエン
酸、酒石酸、マレイン酸、オキサロ酢酸、イソクエン酸
及びリンゴ酸からなる群から選ばれた一種又は二種以上
であり、積層製剤が、核、第一層、第二層及び第三層の
順に積層される多層構造を有し、核が塩化ナトリウムで
ある透析用剤において、第一層はカルシウム塩又は/及
びマグネシウム塩を含み有機酸及び重炭酸塩を含まない
層であり、第二層は有機酸を含みカルシウム塩、マグネ
シウム塩及び重炭酸塩を含まない層であり、第三層は重
炭酸塩を含みカルシウム塩、マグネシウム塩及び有機酸
を含まない層であることを特徴とする重曹透析用剤。
1. A dialysis agent containing an electrolyte, an organic acid and glucose, wherein the organic acid is selected from the group consisting of acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid. In the dialysis agent having a multilayer structure in which a core, a first layer, a second layer and a third layer are laminated in this order, and the core is sodium chloride, One layer is a layer containing calcium salt and / or magnesium salt and no organic acid and bicarbonate salt, the second layer is a layer containing organic acid and no calcium salt, magnesium salt and bicarbonate salt, A sodium bicarbonate dialysis agent, wherein the three layers are layers containing bicarbonate and not containing calcium salt, magnesium salt and organic acid.
【請求項2】 前記第二層が内層及び外層の二層に分け
て積層され、内層に少なくとも有機酸が含まれることを
特徴とする請求項1に記載の重曹透析用剤。
2. The sodium bicarbonate dialysis agent according to claim 1, wherein the second layer is divided into two layers, an inner layer and an outer layer, and the inner layer contains at least an organic acid.
【請求項3】 前記第二層が内層、中間層及び外層の三
層に分けて積層され、内層又は中間層に少なくとも有機
酸が含まれ、外層に少なくとも塩化ナトリウムが含まれ
ることを特徴とするとする請求項1に記載の重曹透析用
剤。
3. The second layer is divided into three layers of an inner layer, an intermediate layer and an outer layer, and the inner layer or the intermediate layer contains at least an organic acid, and the outer layer contains at least sodium chloride. The sodium bicarbonate dialysis agent according to claim 1.
【請求項4】 積層製剤が、防湿を施した容器に乾燥剤
と共に収納され、かつ容器内が、炭酸ガスで置換される
ことを特徴とする請求項1,2又は3に記載の重曹透析
用剤。
4. The sodium bicarbonate dialysis according to claim 1, wherein the laminated preparation is stored together with a desiccant in a moisture-proof container, and the inside of the container is replaced with carbon dioxide gas. Agent.
【請求項5】 結合剤としてブドウ糖溶液を用いて積層
することを特徴とする重曹透析用剤の製造方法。
5. A method for producing a sodium bicarbonate dialysis agent, which comprises laminating a glucose solution as a binder.
JP16994594A 1994-06-28 1994-06-28 Sodium bicarbonate dialysis agent and method for producing the same Expired - Fee Related JP3647898B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16994594A JP3647898B2 (en) 1994-06-28 1994-06-28 Sodium bicarbonate dialysis agent and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16994594A JP3647898B2 (en) 1994-06-28 1994-06-28 Sodium bicarbonate dialysis agent and method for producing the same

Publications (2)

Publication Number Publication Date
JPH08169836A true JPH08169836A (en) 1996-07-02
JP3647898B2 JP3647898B2 (en) 2005-05-18

Family

ID=15895802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16994594A Expired - Fee Related JP3647898B2 (en) 1994-06-28 1994-06-28 Sodium bicarbonate dialysis agent and method for producing the same

Country Status (1)

Country Link
JP (1) JP3647898B2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11343230A (en) * 1998-05-27 1999-12-14 Nissho Corp Solid sodium bicarbonate dialysis agent
EP1059083A3 (en) * 1999-06-07 2001-10-04 Nipro Corporation A solid pharmaceutical preparation for dialysis and a process for producing the same
GB2417420A (en) * 2004-08-19 2006-03-01 Aksys Ltd Citrate-based dialysate formulations
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US7208479B2 (en) 1998-12-04 2007-04-24 Baxter International, Inc. Peritoneal dialysis solution containing modified icodextrins
JP2008007524A (en) * 2007-09-21 2008-01-17 Nipro Corp Solid baking soda dialysis agent
JP2008007523A (en) * 2007-09-21 2008-01-17 Nipro Corp Solid baking soda dialysis agent
JP2010174020A (en) * 2010-03-01 2010-08-12 Nipro Corp Solid agent for sodium bicarbonate dialysis
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
WO2014057966A1 (en) * 2012-10-10 2014-04-17 富田製薬株式会社 Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same
CN109432123A (en) * 2018-11-23 2019-03-08 济南康和医药科技有限公司 A kind of compound electrolyte glucose injection and preparation method thereof
WO2023195304A1 (en) * 2022-04-08 2023-10-12 富田製薬株式会社 Agent a for hemodialysis, and hemodialysis agent
WO2025144780A1 (en) 2023-12-27 2025-07-03 Baxter International Inc. Solid pharmaceutical preparation for peritoneal dialysis and process for producing the same

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11343230A (en) * 1998-05-27 1999-12-14 Nissho Corp Solid sodium bicarbonate dialysis agent
US7208479B2 (en) 1998-12-04 2007-04-24 Baxter International, Inc. Peritoneal dialysis solution containing modified icodextrins
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US8158157B2 (en) 1999-04-26 2012-04-17 Baxter International Inc. Multi-part substitution infusion fluids and matching anticoagulants
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US8795517B2 (en) 1999-04-26 2014-08-05 Nikkiso Co., Ltd. Machine readable medium embodying instructions for citrate anticoagulation system for extracorporeal blood treatments
US7758900B2 (en) 1999-04-26 2010-07-20 Baxter International Inc. Multi-part substitution infusion fluids and matching anticoagulants
US8529486B2 (en) 1999-04-26 2013-09-10 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US6489301B1 (en) 1999-06-07 2002-12-03 Nipro Corporation Solid pharmaceutical preparation for dialysis and a process for producing the same
EP1059083A3 (en) * 1999-06-07 2001-10-04 Nipro Corporation A solid pharmaceutical preparation for dialysis and a process for producing the same
GB2417420A (en) * 2004-08-19 2006-03-01 Aksys Ltd Citrate-based dialysate formulations
JP2008007523A (en) * 2007-09-21 2008-01-17 Nipro Corp Solid baking soda dialysis agent
JP2008007524A (en) * 2007-09-21 2008-01-17 Nipro Corp Solid baking soda dialysis agent
JP2010174020A (en) * 2010-03-01 2010-08-12 Nipro Corp Solid agent for sodium bicarbonate dialysis
WO2014057966A1 (en) * 2012-10-10 2014-04-17 富田製薬株式会社 Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same
CN109432123A (en) * 2018-11-23 2019-03-08 济南康和医药科技有限公司 A kind of compound electrolyte glucose injection and preparation method thereof
CN109432123B (en) * 2018-11-23 2021-07-20 济南康和医药科技有限公司 Compound electrolyte glucose injection and preparation method thereof
WO2023195304A1 (en) * 2022-04-08 2023-10-12 富田製薬株式会社 Agent a for hemodialysis, and hemodialysis agent
JP2023155050A (en) * 2022-04-08 2023-10-20 富田製薬株式会社 Agent a for hemodialysis, and hemodialysis agent
WO2025144780A1 (en) 2023-12-27 2025-07-03 Baxter International Inc. Solid pharmaceutical preparation for peritoneal dialysis and process for producing the same

Also Published As

Publication number Publication date
JP3647898B2 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
US6489301B1 (en) Solid pharmaceutical preparation for dialysis and a process for producing the same
EP0602014B2 (en) Preparation for blood dialysis and method for production thereof
EP0177614B1 (en) Process for producing mixed electrolyte powder for use in bicarbonate dialysis
EP1192961B1 (en) Solid preparation for dialysis and process for producing the same
EP2151247B1 (en) Solid dialysis preparation
JPH08169836A (en) Agent for sodium bicarbonate dialysis and its production
JPH1087478A (en) Bicarbonate solid agent for dialysis
JP3530235B2 (en) Hemodialysis agent
JP6366214B1 (en) Agent A for hemodialysis
JP3384841B2 (en) Baking soda dialysis agent
CN100558344C (en) Solid preparation for dialysis and method for producing same
JP3398184B2 (en) Dialysis agent
JP3415291B2 (en) Bicarbonate dialysis agent
JPH02311418A (en) Pharmaceutical for hemodialysis and its production
CN1938058A (en) Solid pharmaceutical preparation for dialysis
JP4603977B2 (en) Dialysis solid preparation and method for producing the same
JPH10259133A (en) Granular dialysis agent and method for producing the same
JPH11114054A (en) Solid dialysis agent
JPH0338527A (en) Preparation for blood dialysis and its production
EP1086700B1 (en) A solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same
JPH0724061A (en) Prepation for hemodialysis
JP3951284B2 (en) Solid preparation for dialysis and method for producing the same
JP4328851B2 (en) Bicarbonate solid dialysate
WO2004066977A1 (en) Solid agent for dialysis and process for producing the same
JP6312957B1 (en) Agent A for hemodialysis

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041109

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050210

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090218

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090218

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100218

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100218

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110218

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110218

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees